Presentation Title

Omega-3 fatty acids protect cognition of MCI patients beyond cholinesterase inhibitors, and improve energy and amyloid-β phagocytosis

Faculty Mentor

Milan Fiala

Start Date

23-11-2019 10:00 AM

End Date

23-11-2019 10:45 AM

Location

89

Session

poster 3

Type of Presentation

Poster

Subject Area

biological_agricultural_sciences

Abstract

The cholinesterase inhibitor (CI) therapeutics approved for use in Alzheimer disease (AD) do not clear amyloid-β (Aβ) neuropathology and are palliative only for 6 to 9 months. An omega-3 (ω-3) fatty acid emulsion improves phagocytosis of Aβ by monocyte/macrophages (MM) of Mild cognitive impairment (MCI) patients through transcriptional regulation and energetic effects. We performed an observational study of seven Subjective cognitive impairment (SCI) and eight MCI patients on supplementation by the ω-3 drink Smartfish. The MCI patients had double therapy by CI therapeutics. We examined cognition according to Minimental state examination (MMSE) score and immune response according to Aβ blood test (Mean Fluorescence Intensity (MFI)). The Aβ test results were >150,000 U. in normal controls, 100,000 to 150,000 U. in SCI patients,100,000 after ω-3 therapy in most MCI and AD patients. The test may be useful as a screening test for early AD and a follow- up test of patients on ω-3 supplementation. After starting ω-3 supplementation, four MCI patients previously failing CI therapy remained cognitively stable for 2 to 3.5 years and then declined, and three MCI patients improved in a short term. Cognitive improvement of an 87-year old patient was associated with increased transcripts of glycolysis and tricarboxylic cycle energy enzymes. In conclusion, ω-3 may provide increased energy for Aβ phagocytosis and neuronal homeostasis. The results in our small study support benefits of combined CI with ω-3 therapy on recovery after surgery and protection from MCI progression, however, need confirmation in a clinical trial.

This document is currently not available here.

Share

COinS
 
Nov 23rd, 10:00 AM Nov 23rd, 10:45 AM

Omega-3 fatty acids protect cognition of MCI patients beyond cholinesterase inhibitors, and improve energy and amyloid-β phagocytosis

89

The cholinesterase inhibitor (CI) therapeutics approved for use in Alzheimer disease (AD) do not clear amyloid-β (Aβ) neuropathology and are palliative only for 6 to 9 months. An omega-3 (ω-3) fatty acid emulsion improves phagocytosis of Aβ by monocyte/macrophages (MM) of Mild cognitive impairment (MCI) patients through transcriptional regulation and energetic effects. We performed an observational study of seven Subjective cognitive impairment (SCI) and eight MCI patients on supplementation by the ω-3 drink Smartfish. The MCI patients had double therapy by CI therapeutics. We examined cognition according to Minimental state examination (MMSE) score and immune response according to Aβ blood test (Mean Fluorescence Intensity (MFI)). The Aβ test results were >150,000 U. in normal controls, 100,000 to 150,000 U. in SCI patients,100,000 after ω-3 therapy in most MCI and AD patients. The test may be useful as a screening test for early AD and a follow- up test of patients on ω-3 supplementation. After starting ω-3 supplementation, four MCI patients previously failing CI therapy remained cognitively stable for 2 to 3.5 years and then declined, and three MCI patients improved in a short term. Cognitive improvement of an 87-year old patient was associated with increased transcripts of glycolysis and tricarboxylic cycle energy enzymes. In conclusion, ω-3 may provide increased energy for Aβ phagocytosis and neuronal homeostasis. The results in our small study support benefits of combined CI with ω-3 therapy on recovery after surgery and protection from MCI progression, however, need confirmation in a clinical trial.